期刊文献+

体外构建双H1启动子SECs及其对HepG2细胞端粒酶活性的干扰作用 被引量:4

The interfering effect of construction of double-H1 promoters SECs on telomerase gene expression in HepG2 cells
原文传递
导出
摘要 目的构建针对端粒酶hTERT的双H1启动子SECs,并探讨其转录生成的siRNA对HepG2细胞端粒酶活性的抑制作用。方法利用融合PCR技术,构建2个针对人端粒酶hTERT基因外显子不同片断的双H1启动子SECs,分别转染人肝癌细胞HepG2,转录生成siRNAs。用TRAP法和PCR-EIA法检测端粒酶活性,分析双H1启动子SECs对HepG2细胞端粒酶表达的干扰作用。结果成功构建针对hTERT的双H1启动子SECs,其转录产物siRNA可明显抑制HepG2细胞端粒酶的活性。结论siRNA SECs对HepG2细胞端粒酶hTERT基因表达有明显的干扰作用,为临床开展对肿瘤端粒酶基因干扰抑制的实验研究奠定了基础。 Objective To construct the double-H1promoters siRNA expression cassettes (SECs) targeted to human telomere retrotranscriptase ( hTERT ) , and investigate the interfering effect of its siRNA on hTERT gene expression in HepG2 cells. Methods SECs were constructed by fusing PCR, based on two different human telomerase hTERT gene fragments. When SEGs transferred into HepG2 cells respectively, the SECs were transcripted to the siRNA. The interfering effect of SECs on the telomerase activity in the cells was assessed by telomeric repeat amplification protocol (TRAP) and PCR-EIA. Results SEGs were successful constracted, and the telomerase activity was significantly inhibited when the HepG2 cells were tranfected with SECs. Conclusions The siRNA SECs display a definite RNA interference effect on the expression of telomerase. This method of SECs preparation can be applied for RNAi research in tumor inhibition.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2009年第1期53-57,共5页 China Journal of General Surgery
基金 湖南省科技厅课题资助(98SSY1003)
关键词 RNA干扰 端粒酶逆转录酶 H1启动子 SECs 人肝癌细胞 RNA Interference hTERT H1 Promoter SECs HepG2 Cells
  • 相关文献

参考文献21

  • 1Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs [ J ]. Genes, 2001,15(2) :188 -200.
  • 2Kim D, Rossi J. RNAi mechanisms and applications [ J ]. Biotechniques, 2008 , 44 ( 5 ) : 613 - 616.
  • 3Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies [ J ]. Cancer Res,2008,68(5) :1247 - 1250.
  • 4Greeter CW, Blackburn EH. Identification of a specific telomere lariminol transferase activity in Tetrahymena extracts [J]. Cell,1985,43 (2) :405 -413.
  • 5Shay JW, Bacchetti S. A survey of telomerase activity in human cancer[J]. Cancer, 1997,5(33) :787 -791.
  • 6Shay JW, Woodring EW. Telomerase therapeutics for cancer: challenges and new directions [ J ]. Nature Rev Drug Discov, 2006,5(7) :577 -584.
  • 7Harley CB. Telomerase and cancer therapeutics [ J ]. Nat Rev Cancer, 2008,8(3) :167 -179.
  • 8陈波,邹声泉.端粒酶在肿瘤诊断与辅助治疗中的潜在应用价值[J].中国普通外科杂志,2005,14(10):780-782. 被引量:3
  • 9J.萨姆布鲁克,E.F.弗里奇,等.分子克隆实验指南[M].第3版.北京:科学出版社,2000:1290-1291.
  • 10Kim NW, Piatyszek MA, Prowse R, et al. Specific association of human telomerase activity with immortal cells and cancers[J].Science,1994,266(5193) :2011 -2015.

二级参考文献50

共引文献13

同被引文献52

  • 1程文,位志峰,高建平,张征宇,葛京平,景抗震,徐锋,解鹏.Effects of Combined siRNA-TR and-TERT on Telomerase Activity and Growth of Bladder Transitional Cell Cancer BIU-87 Cells[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2010,30(3):391-396. 被引量:3
  • 2Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391(6669):806-811.
  • 3Tuschl T. RNA interference and small interfering RNAs[J]. Chembiochem, 2001, 2(4):239-245.
  • 4Kim D, Rossi J. RNAi mechanisms and applications[J]. Biotechniques, 2008, 44(5):613-616.
  • 5Hu Y, Shen Y, Ji B, et al. Combinational RNAi gene therapy of hepatocellular carcinoma by targeting human EGFR and TERT[J]. Eur J Pharm Sci, 2011, 42(4):387-391.
  • 6Fang L, Cheng Q, Li W, et al. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells[J]. Virus Res, 2014, 181:61-71.
  • 7Shen Y, Zhang YW, Zhang ZX, et al. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells[J]. Cancer Biol Ther, 2008, 7(2):228-236.
  • 8Ge L, Deng Z, Zhang Y, et al. Effect of plasmid-mediated RNA interference targeting telomerase reverse transcriptase on lung cancer cells[J]. Oncol Rep, 2011, 26(6):1487-1495.
  • 9Amarzguioui M, Rossi JJ, Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi[J]. FEBS Lett, 2005, 579(26):5974-5981.
  • 10Li X, Li Y, Hu J, et al. Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo[J]. Cancer Lett, 2013, 335(1):242-250.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部